{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sharma N"],"funding":["Korea Institute of Marine Science & Technology Promotion (KIMST)","Ministry of Education","Kementerian Pendidikan","National Research Foundation of Korea"],"pagination":["e70475"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12290491"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["21(7)"],"pubmed_abstract":["Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder, predominantly affecting the aging population. Early detection through biomarkers is essential for early intervention. Recent sub-classification of AD through extensive cerebrospinal fluid (CSF) proteomic analyses revealed distinct characteristics of each subtype, necessitating tailored therapeutic strategies. While CSF proteomics has identified potential biomarkers, the need for non-invasive and cost-effective substitutions highlights the importance of blood-based biomarkers (BBMs). This review is a comprehensive review that categorizes potential BBMs based on neuronal hyperplasticity (subtype 1), underlining their role in refining subtype classification and enabling precision medicine. Early AD is often marked by c"],"journal":["Alzheimer's & dementia : the journal of the Alzheimer's Association"],"pubmed_title":["Unveiling blood biomarkers for neuronal hyperplasticity: Insights from AD molecular subtyping, a comprehensive review."],"pmcid":["PMC12290491"],"funding_grant_id":["RS‐2021‐NR060117","RS-2021-NR060117","RS‐2023‐00251396","RS-2023-00251396","2021R1A6A1A03038996","RS-2025-02292973"],"pubmed_authors":["Oh HJ","Kim D","Scheltens P","An SSA","Kim GH","Lee H","Han S","Zetterberg H","Kim M","Park YH","Teunissen C","Kim MI","Kang MJ","Sharma N","Ryu J","Yang HS","Sharma H","Youn YC","Kim HR","Kim YB","Kim S","Pyun JM","Alzheimer's Disease All Markers (ADAM) Research Group","Yang Y","Ryoo N"],"additional_accession":[]},"is_claimable":false,"name":"Unveiling blood biomarkers for neuronal hyperplasticity: Insights from AD molecular subtyping, a comprehensive review.","description":"Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder, predominantly affecting the aging population. Early detection through biomarkers is essential for early intervention. Recent sub-classification of AD through extensive cerebrospinal fluid (CSF) proteomic analyses revealed distinct characteristics of each subtype, necessitating tailored therapeutic strategies. While CSF proteomics has identified potential biomarkers, the need for non-invasive and cost-effective substitutions highlights the importance of blood-based biomarkers (BBMs). This review is a comprehensive review that categorizes potential BBMs based on neuronal hyperplasticity (subtype 1), underlining their role in refining subtype classification and enabling precision medicine. Early AD is often marked by c","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jul","modification":"2026-07-15T05:56:26.323Z","creation":"2025-08-13T03:04:15.194Z"},"accession":"S-EPMC12290491","cross_references":{"pubmed":["40709526"],"doi":["10.1002/alz.70475"]}}